神経痛治療薬市場：薬剤の種類別、投与経路別、重症度別、流通チャネル別、地域別

世界の神経痛治療薬市場は、2024年には24億1,000万米ドルと推定され、2031年には37億2,000万米ドルに達すると予測され、2024年から2031年までのCAGRは6.4%です。

図：神経痛治療薬の市場シェア (%)、2024年、地域別

神経痛は神経障害性疼痛としても知られ、体性感覚神経系に影響を及ぼす損傷や疾患によって引き起こされる慢性疼痛です。大げさに感じたり、予測できないような、撃つような、刺すような、鋭い痛みが特徴です。神経痛の一般的なタイプには、三叉神経痛、帯状疱疹による帯状疱疹後神経痛、線維筋痛症などがあります。世界の神経痛治療薬市場は、神経障害性疼痛疾患の有病率の上昇と、そのような状態に陥りやすい老年人口の増加により、ここ数年で成長を遂げています。さらに、効能が向上し、副作用が最小限に抑えられた新薬の開発も、神経痛治療薬への需要を後押ししています。

市場力学：

世界の神経痛治療薬市場は、世界の老年人口の増加と相まって、神経障害性疼痛疾患の発生率が増加していることが要因となっています。神経障害性疼痛疾患は、加齢に伴う神経系の退行性変化により、高齢者に多く見られます。さらに、従来の治療法よりも高い有効性と良好な安全性プロファイルを提供する新薬の市場開拓が、市場の成長を促進しています。カルバマゼピンとガバペンチンは、神経痛の治療によく使われる特許切れ薬です。しかし、これらの薬剤は忍容性に問題があり、コンプライアンスが悪いです。このため、ナトリウムチャネル遮断薬、NMDA受容体拮抗薬、α2δリガンドなど、リスク・ベネフィットが改善された新規治療薬の研究開発が進められています。一方、疾患修飾性治療薬の不足や新しい治療薬の高価格は、市場拡大をある程度抑制する課題となっています。とはいえ、疼痛管理に対する意識の高まりや、ブランド薬のジェネリック医薬品が入手可能であることは、神経痛治療薬市場のプレーヤーにとって、今後数年間で大きなビジネスチャンスを生み出すことになります。

当研究の主な特徴

当レポートでは、世界の神経痛治療薬市場を詳細に分析し、2023年を基準年とした予測期間 (2024-2031年) の市場規模 (10億米ドル) および複合年間成長率 (CAGR%) を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の発売や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。

世界の神経痛治療薬市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。

当研究の対象となる主要企業には、グラクソ・スミスクラインPLC、ファイザーInc.、ノバルティス AG、バイオジェン、カディラ・ヘルスケア・リミテッド、ルンドベック・ファーマシューティカルズ LLC、テバ・ファーマシューティカル・インダストリーズ・リミテッド、サノフィ S.A.、アムジェンInc.、イーライリリー・アンド・カンパニー、アステラス製薬、ジョンソン・エンド・ジョンソン、メルク・アンド・カンパニー、アッヴィ・インク、H.ルンドベック A/Sなどがあります。

当レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の神経痛治療薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

利害関係者は、世界の神経痛治療薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 分析目的と前提条件

• 分析目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学・規制・動向の分析

• 市場力学
• 促進要因
• 抑制要因
• 影響分析
• 主な動向
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• Porterの分析
• 企業合併・買収 (M&A) のシナリオ
• 業界動向

第4章 世界の神経痛治療薬市場：薬剤の種類別、2019～2031年 (10億米ドル)

• 抗けいれん薬
• 抗うつ薬
• オピオイド
• 非ステロイド性抗炎症薬 (NSAID)
• その他

第5章 世界の神経痛治療薬市場：投与経路別、2019～2031年 (10億米ドル)

• 経口
• 静脈内
• 経皮
• その他

第6章 世界の神経痛治療薬市場：重症度別、2019～2031年 (10億米ドル)

• 軽度
• 中度
• 重度

第7章 世界の神経痛治療薬市場：流通チャネル別、2019～2031年 (10億米ドル)

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の神経痛治療薬市場：種類別、2019～2031年 (10億米ドル)

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• GlaxoSmithKline PLC
• Pfizer Inc.
• Novartis AG
• Biogen
• Cadila Healthcare Limited
• Lundbeck Pharmaceuticals LLC
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Amgen Inc.
• Eli Lilly and Company
• Astellas Pharma Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• AbbVie Inc.
• Lundbeck A/S

第10章 アナリストの提言

• 「運命の輪」
• アナリストの見解
• Coherent Opportunity Map (COM)

第11章 参考文献と調査手法

• 参考文献
• 分析手法
• Coherent Market Insightsについて

The global neuralgia treatment market is estimated to be valued at USD 2.41 Bn in 2024 and is expected to reach USD 3.72 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2031.

Figure. Neuralgia Treatment Market Share (%), By Region 2024

Neuralgia, also known as neuropathic pain, is a chronic pain caused by damage or disease affecting the somatosensory nervous system. It is characterized by shooting, stabbing, and sharp pain that feels exaggerated or unpredictable. Some common types of neuralgia include trigeminal neuralgia, postherpetic neuralgia caused by shingles, and fibromyalgia. The global neuralgia treatment market has been witnessing growth in recent times owing to the rising prevalence of neuropathic pain disorders and growing geriatric population who are more prone to such conditions. Furthermore, the development of novel drugs providing improved efficacy and minimal side effects are also fueling the demand for neuralgia treatments.

Market Dynamics:

The global neuralgia treatment market is driven by the increasing incidence of neuropathic pain disorders coupled with the growing geriatric population globally. Neuropathic pain conditions are more prevalent in the elderly due to age-related degenerative changes in the nervous system. Additionally, the market growth is facilitated by the development of newer drugs offering enhanced efficacy and favorable safety profiles over conventional treatment options. Carbamazepine and gabapentin are off-patent drugs commonly used to treat neuralgia. However, their tolerability issues lead to poor compliance. This has triggered R&D of novel therapeutic classes like sodium channel blockers, NMDA receptor antagonists, and alpha-2 delta ligands that demonstrate improved risk-benefit ratios. On the other hand, lack of disease-modifying treatments and high cost of newer therapies are some challenges restraining the market expansion to a certain extent. Nevertheless, rise in awareness about pain management and availability of generic versions of branded drugs create huge opportunities for the neuralgia treatment market players in the coming years.

Key Features of the Study:

This report provides in-depth analysis of the global neuralgia treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global neuralgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GlaxoSmithKline PLC, Pfizer Inc., Novartis AG, Biogen, Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Amgen Inc., Eli Lilly and Company, Astellas Pharma Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., and H. Lundbeck A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global neuralgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuralgia treatment market

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Anticonvulsants
  • Antidepressants
  • Opioids
  • Non-steroidal anti-inflammatory Drugs (NSAIDs)
  • Others
• Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
  • Oral
  • Intravenous
  • Transdermal
  • Others
• Severity Insights (Revenue, USD Bn, 2019 - 2031)
  • Mild
  • Moderate
  • Severe
• Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Novartis AG
  • Biogen
  • Cadila Healthcare Limited
  • Lundbeck Pharmaceuticals LLC
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Amgen Inc.
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Lundbeck A/S

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Neuralgia Treatment Market, By Drug Type
  • Global Neuralgia Treatment Market, By Route of Administration
  • Global Neuralgia Treatment Market, By Severity
  • Global Neuralgia Treatment Market, By Distribution Channel
  • Global Neuralgia Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Neuralgia Treatment Market, By Drug Type, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Anticonvulsants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Antidepressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Opioids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Non-steroidal anti-inflammatory Drugs (NSAIDs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Neuralgia Treatment Market, By Route of Administration, 2019-2031 (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Transdermal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Neuralgia Treatment Market, By Severity, 2019-2031, (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Mild
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Moderate
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Severe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Neuralgia Treatment Market, By Distribution Channel, 2019-2031 (USD Bn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Neuralgia Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Severity, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cadila Healthcare Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Amgen Inc.
• Eli Lilly and Company
• Astellas Pharma Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• AbbVie Inc.
• Lundbeck A/S

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us